In this study, 9-benzylidene-9H-fluorene-substituted urea (5a-p) and thiourea derivatives (5q-v) were synthesized and their inhibitory effects on the activity of human carbonic anhydrase (hCA) I and II were evaluated. hCA I and II were purified from human erythrocytes using a Sepharose 4B-L-tyrosinesulphanilamide affinity column. All the synthesized compounds inhibited the activity of the hCA I and II isoenzymes. Among the synthesized compounds, 5f was found to be the most active (IC 50 = 21.4 μM) for inhibition of hCA I and 5s was the most active (IC 50 = 25.3 μM) for inhibition of hCA II.
INTRODUCTION
Fluorene-containing compounds have unique chemical behaviours and physical properties due to the unusual geometric structure of fluorene [1] . Fluorene and its derivatives are important materials that are used in organic synthesis, the pharmaceutical and synthetic resin industries, and conductivity research [2] [3] [4] . Acetylamino-, diacetylamino-, amino-and nitro-substituted fluorene compounds increase the biological effects [5, 6] of an inhibitor of oncogenic tyrosine kinase [7] , antimicrobial agents [8] and potent frameshift-type mutagens [9] . Many compounds containing a styryl group have been used as enzyme inhibitors. Some 9-benzylidene-9H-fluorene derivatives containing styryl groups may be suitable candidates for CA inhibition [10] .
Due to their biological activities, substituted urea and thiourea compounds have potential as chemotherapeutic agents [11, 12] , HIV protease inhibitors [13] , tyrosinase inhibitors [14, 15] , herbicides and antifungal agents [16] . In addition, recent studies have shown that different urea derivatives have dopamine hydroxylase inhibitory properties, and dopamine is a key precursor of norepinephrine [17] . Also, they are an intermediate product in various total synthesis [18] . Urea derivatives show interesting profiles for the inhibition of several human carbonic anhydrases (hCAs) such as hCA I and II (cytosolic isoforms) and hCA IX and XII (transmembrane, tumour-associated enzymes). The compounds have good inhibitory effects for all these isoforms due to the urea moiety [19] .
The metalloenzyme CA (EC 4.2.1.1) catalyses a simple but critically important physiological reaction: members of the CA enzyme family catalyse hydration of CO 2 to yield bicarbonate and a proton. As this reaction is involved in many physiological/pathological processes, there are widespread opportunities for the development of diverse, specific inhibitors for clinical application [20] [21] [22] [23] .
The active site of most CAs contains a zinc ion (Zn 2+ ) that is essential for catalysis. The CA reaction is involved in many physiological and pathological processes, including: respiration and transport of CO 2 and bicarbonate between metabolizing tissues and lungs; pH and CO 2 homeostasis; electrolyte secretion in various tissues and organs; biosynthetic reactions such as gluconeogenesis, lipogenesis and ureagenesis; bone resorption; calcification; and tumourigenicity [24] [25] [26] [27] [28] [29] [30] . Many of the CA isoenzymes involved in these processes are important therapeutic targets with the potential to be inhibited and to treat a range of disorders, including oedema, glaucoma, obesity, cancer, epilepsy and osteoporosis [31] [32] [33] [34] [35] .
In this study, a series of 22 novel 9-benzylidene-9H-fluorene derivatives (5a-v) containing urea/thiourea groups were synthesized and their effects on hCA I and II purified from human erythrocytes were evaluated.
MATERIALS AND METHODS
Melting points of the synthesized fluorene derivatives were determined by Yanagimoto micro-melting point apparatus and were uncorrected. IR spectra were measured on a Shimadzu Prestige-21 (200 VCE) spectrometer. C chemical shifts were referenced to the internal deuterated solvent. The elemental analyses were carried out with a Leco CHNS-932 instrument. Flash column chromatography was performed using Merck silica gel 60 (230-400 mesh ASTM). All chemicals were purchased from Merck, Alfa Easer and Sigma-Aldrich.
Synthesis of 2-nitro-9-benzylidene-9-H-fluorene (3)
2-Nitro-9-benzylidene-9H-fluorene (3) was prepared according to the literature [36] . 2-nitrofluorene (4.22 g, 20 mmol) and KOH (3 g, 50 mmol) were stirred in methanol for 30 minutes. Benzaldehyde (2.12 g, 20 mmol) was added and stirred overnight at room temperature. Solvent was evaporated using a rotary evaporator. The mixture was extracted with ethyl acetate (3 × 20 ml). The product was purified by washing with diethyl ether.
Synthesis of 2-amino-9-benzylidene-9H-fluorene (4a-b)
2-Amino-9-benzylidene-9H-fluorene was prepared according to the literature [37] . The mixture of 9-benzylidene-2-nitro-9H-fluorene (2.99 g, 10 mmol) and SnCl 2 (11.3 g, 50 mmol) in THF was refluxed for 7 h. THF was removed using a rotary evaporator, and the mixture was extracted with ethyl acetate (3 × 20 ml). At the end of the reaction, two products (including E-and Z-) were obtained. The products (E-and Z-) were purified by column chromatography on silica gel using hexane: ethyl acetate (9:1).
General procedure for the synthesis of (E or Z)-1-(9-benzylidene-9H-fluoren-2-yl)-3-phenylurea (5a-p)
Isocyanate derivatives (10 mmol) were added to a solution of 2-amino-9-benzylidene-9H-fluorene (E-or Z-) (2.68 g, 10 mmol) in toluene. The mixture was stirred at 65 ºC until precipitation. Toluene was removed using a rotary evaporator, and the product was purified by washing with ethyl ether.
General procedure for the synthesis of (E or Z)-1-(9-benzylidene-9H-fluoren-2-yl)-3-phenylthiourea (5q-v)
Isothiocyanate derivatives (10 mmol) were added to a solution of 2-amino-9-benzylidene-9H-fluorene (E-or Z-) (2.68 g, 10 mmol) in DMF. The mixture was stirred at 40 ºC until precipitation. The precipitated product was filtered and washed with a few drops of ethyl ether. 1-(9-benzylidene-9H-fluoren-2-yl)-3-(3,4- 3. CA ENZYME ASSAY
Preparation and purification of haemolysate from red blood cells
Blood samples (25 ml) were taken from healthy human volunteers. They were anticoagulated with acid-citrate-dextrose, centrifuged at 5000 rpm for 20 min at 4 ºC and the supernatant was removed. The packed erythrocytes were washed three times with 0.9 % NaCl and then haemolysed in cold water. The ghosts and any intact cells were removed by centrifugation at 15000 rpm for 25 min at 4 ºC, and the pH of the haemolysate was adjusted to pH 8.5 with solid Tris-base. The haemolysate (25 ml) was applied to an affinity column containing -sulfonamide-Ltyrosine -Sepharose-4B [38] equilibrated with 25 mM Tris-HCl/0.1 M Na 2 SO 4 (pH 8.5). The affinity gel was washed with 50 ml of 25 mM Tris-HCl/22 mM Na 2 SO 4 (pH 8.5). The human CA (hCA) isozymes were then eluted with 0.1 M NaCl/25 mM Na 2 HPO 4 (pH 6.3) and 0.1 M CH 3 COONa/0.5 M NaClO 4 (pH 5.6), which recovered hCA I and II respectively. Fractions of 3 ml were collected and their absorbance measured at 280 nm.
In vitro inhibition studies
CA activity was measured by the Maren method, which is based on determination of the time required for the pH to decrease from 10.0 to 7.4 due to CO 2 hydration [39] . The assay solution was 0.5 M Na 2 CO 3 /0.1 M NaHCO 3 (pH 10.0) and phenol red was added as the pH indicator. CO 2 -hydratase activity (enzyme units (EU)) was calculated by using the equation (t 0 -t c )/t c where t 0 and t c are the times for pH change of the non-enzymatic and the enzymatic reactions, respectively.
For the inhibition studies of synthesized compounds, different concentrations of these compounds were added to the enzyme. Activity percentage values of CA for each concentration of each compound were determined by regression analysis using Microsoft Office 2000 Excel. CA enzyme activity without urea solution was deemed to be 100%.
RESULTS AND DISCUSSION
2-Nitro-9-benzylidene-9H-fluorene (3) was synthesized from 2-nitrofluorene (1) and the compound was reduced with tin (II) chloride in THF. The E-and Z-isomers of 2-nitro-9-benzylidene-9H-fluorene (4a-b) were reacted with isocyanates/isothiocyanates to get the final products (5a-v) at high yields. The synthetic procedures are depicted in Scheme 1. 5a 5b 5c 5d 5e 5f 5g 5h
Scheme 1. Synthesis of (E or Z)-1-(9-benzylidene-9H-fluoren-2-yl)-3-phenylurea/thiourea derivatives
The synthesized compounds were characterized by 1 H NMR, 13 C NMR, IR and elemental analysis. From the 1 H NMR spectra, the resonance due to the hydrogen attached to the amide nitrogen was between 8.50 and 10.00 ppm. The signals for aromatic and vinylic protons were between 7.00 and 8.50 ppm. From the 13 C NMR spectra, carbon atoms of urea carbonyl were observed between 182 and 150 ppm. In the infrared spectra of compounds 5a-v, it was possible to observe the absorptions between 3250 and 3450 cm -1 relating to N-H stretching and absorptions at 1650-1750 cm -1 from the urea carbonyl moiety stretching. Furthermore, absorptions between 1180 and 1280 cm -1 indicated C-N stretching.
To evaluate the hCA I and II inhibitory effects, all compounds were subjected to hCA I and II inhibition assays with CO 2 as a substrate. The results showed that these compounds (5a-v) inhibited the CA enzyme activity. The IC 50 values of 5a-v analogues for hCA I and II are summarized in Table 1 . The IC 50 values were between 21.4 and 211.4 μM for hCA I enzyme activity and between 25.3 and 82.4 μM for hCA II. Among the compounds, 5f (IC 50 = 21.4 µM) was found to be the most active compound for hCA I inhibitory activity and 5s (IC 50 = 25.3 µM) showed the highest hCA II inhibitory activity.
T a b l e 1
The IC 50 The following conclusions should be noted regarding the CA inhibitory data of Table 1 .
(i) The slow cytosolic isoform hCA I was inhibited by the 9-benzylidene-9H-fluorene-substituted diaryl urea and thiourea derivatives with inhibition constants in the range 21.4-211.4 µM. The best hCA I inhibitor among the novel compounds was 5f. E-isomers of urea and thiourea compounds, which do not have any group at the phenyl ring, showed a higher inhibitory effect than Z-isomers for hCA I. A methoxy group at the phenyl ring had a greater inhibitory effect for hCA I than for hCA II, while a methyl group at the phenyl ring had a higher inhibitory effect for hCA II than for hCA I.
(ii) The second off-target isoform (hCA II), which is in fact the physiologically dominant cytosolic isozyme, was also inhibited by all the compounds with inhibition constants in the range 25.3-82.4 µM. The best hCA II inhibitor among the novel compounds was 5s. Z-isomers of the synthesized compounds were generally more effective in the inhibition of hCA II. Both Z-and E-isomers of the synthesized compounds containing -NO 2 groups at the phenyl ring had a higher inhibitory effect. A chlorine atom at the meta-position of the phenyl ring exhibited a greater inhibitory effect than at the para-position.
In conclusion, we have evaluated the effect of urea (5a-p) and thiourea (5q-v) derivatives on hCA I and II purified from human erythrocytes and structure-activity relationships were examined. The synthesized compounds inhibited the hCA I and II isoenzyme activities. The urea derivatives as inhibitor were bound within the enzyme active site [19, 40] . We assume that the synthesized fluorenecontaining urea/thiourea derivatives inhibited hCA I and II in the same way or that the fluorenyl moiety interacted with the hydrophobic pocket of the enzyme.
In summary, enzyme inhibition is an important issue for drug design and biochemical applications [41] [42] [43] [44] [45] . Our results suggest that these novel compounds are likely to be adopted as candidates for the treatment of glaucoma and that they should be further evaluated in in vivo studies.
